Viridian Therapeutics 3Q 2026: Revenue $25.8M, Net loss $101.2M, EPS $(0.81) — 10-Q Summary

What happened

Viridian Therapeutics reported third-quarter 2026 revenue of $25.8 million and a net loss of $101.2 million. Newly launched veligrotug generated $24.7 million in U.S. product sales, and more than 100 patients had started treatment by September 30. The prior-year quarter included a $70 million Kissei upfront license payment.

Confirmed

Global impact / market context

Veligrotug’s first sales provide an early indication of product revenue after launch, while the reported net loss shows the company remained unprofitable in the quarter. Building U.S. sales, patient support and supply operations may add costs as treatment uptake develops.

Analyst inference

Revenue was lower than the prior-year quarter, which included a $70 million upfront license payment, so the comparison reflects both current product sales and a one-time prior-period payment. Investors may weigh that context against veligrotug’s launch and the company’s continued losses.

Analyst inference

What to watch

1. Track whether veligrotug revenue grows beyond its first reported quarter, and whether patient treatment starts continue to support demand for the newly launched therapy. Analyst inference
2. Viridian anticipates submitting a biologics license application for elegrobart in the first quarter of 2027; watch for that filing and any timing changes. Proposed
3. Phase 1 data for VRDN-008 are expected in the fourth quarter of 2026, while a phase 1 trial of VRDN-292 is planned to begin then. Proposed

Evidence

• Original source link unavailable